A new study reports that microRNA-124-3p directly targets the AHR gene to activate autophagy, suppressing stomach ...
A critical review finds direct clinical evidence for herbal postoperative wound care and early EV feasibility, but no study ...
Ifezuntirgene inilparvovec is the first investigational therapy for Huntington’s disease to have received Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations from the ...
US FDA accepts for review uniQure’s BLA for ifezuntirgene inilparvovec for the treatment of Huntington’s disease: Lexington, Massachusetts Tuesday, November 3, 2026, 16:00 Hrs ...
uniQure N.V. ( QURE ), a gene therapy company, on Monday announced the acceptance of the biologics license application ( BLA) for Ifezuntirgene inilparvovec in treating Huntington's disease by the U.S ...
The FDA has accepted uniQure's Biologics License Application for ifezuntirgene inilparvovec, a one-time gene therapy for Huntington's ...
The Onondaga County Clerk’s office registered 115 home sales during the week of Oct. 8 to 14. The most expensive on the list is a 2,484-square-foot three-bedroom home on 8.7 acres at the edge of the ...
A novel AI tool, circMAC, predicts where microRNAs may bind within full-length circular RNA isoforms at nucleotide resolution.
Circular RNAs (circRNAs) are loop-shaped molecules that can influence gene regulation through interactions with microRNAs (miRNAs). This matters because circRNAs can exist as different full-length ...
Pusan National University Researchers Develop AI Tool to Map MicroRNA Binding Sites on Circular RNAs
circRNA–microRNA interactions can be difficult to map precisely. Researchers developed an AI bioinformatics tool, circMAC, to predict candidate microRNA binding regions within full-length circular RNA ...
MicroRNAs (miRNAs) are small non-coding RNAs that play a central role in post-transcriptional gene regulation. They act mainly by interacting with sequences located ...
The FDA has set a May 1 target action date for uniQure’s Huntington’s disease gene therapy candidate ifezuntirgene inilparvovec, after accepting the company’s Biologics License Application (BLA) under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results